Board of Directors

Our Board of Directors has deep experience and understanding of developing and commercializing novel therapies for unmet medical needs and building and leading successful organizations.

We are honored to have an experienced and well-respected Board of Directors that shares our goal of bringing transformative oral therapies to patients with significant immune-mediated diseases.

Alan B. Colowick M.D., M.P.H., Chair


Dr. Colowick has served on Principia’s Board of Directors as executive chairman since 2017. Since 2017, Dr. Colowick is servings a private equity partner at Sofinnova Ventures. From 2010 to 2017, he held positions at Celgene, including Executive Vice President. From 2008 to 2010, Dr. Colowick was the Chief Executive Officer at Gloucester Pharmaceuticals until its acquisition by Celgene in 2010. From 2006 to 2008, Dr. Colowick was President, Oncology for Geron Corporation and from 2005 to 2006, was Chief Medical Office of Threshold Pharmaceuticals. From 1999 to 2005, Dr. Colowick held senior positions at Amgen.

Dr. Colowick currently serves on the boards of InCarda Therapeutics, VelosBio, XyloCor Therapeutics and Human Longevity. He completed specialty training in Hematology-Oncology at the Dana Farber Cancer Institute/Brigham and Women’s Hospital. Dr. Colowick received a B.S. in Molecular Biology from the University of Colorado, a M.D. from Stanford University, and a M.P.H. from Harvard University.

Martin Babler


Mr. Babler has served as Principia’s Chief Executive Officer since 2011 and as President and Chief Executive Officer since early 2019. From 2007 to 2011, Mr. Babler served as President and Chief Executive Officer of Talima Therapeutics. From 1998 to 2007, Mr. Babler held several positions at Genentech, most notably Vice President, Immunology Sales and Marketing. While at Genentech he also helped to build and led the Commercial Development organization and led the Cardiovascular Marketing organization. From 1991 to 1998, Mr. Babler was employed at Eli Lilly and Company in sales management, global marketing, and business development.

Mr. Babler presently serves on the Emerging Companies Section and Health Section Governing Boards of the Biotechnology Innovation Organization (BIO). Mr. Babler received a Swiss Federal Diploma in pharmacy from the Federal Institute of Technology in Zurich and completed the Executive Development Program at the Kellogg Graduate School of Management at Northwestern University.

Dan Becker, M.D., Ph.D.


Dr. Becker has served on Principia’s Board of Directors since 2017. Dr. Becker joined Access Industries in 2019 as a Principal in the Biotechnology group. From 2015 to 2019, Dr. Becker was a Principal at New Leaf Venture Partners. From 2009 to 2015, Dr. Becker was a Principal at the Boston Consulting Group where he was a core member of their Health Care practice leading projects across the health care sector with an emphasis on biopharma R&D.

From 2006 to 2009, Dr. Becker trained clinically in internal medicine and nephrology at Brigham and Women’s Hospital and Massachusetts General Hospital and was a Research Fellow at Harvard Medical School. Dr. Becker obtained both a M.D. and Ph.D. (Cellular and Molecular Biology) from the University of Michigan and received a B.S. in Physiology from the University of Illinois at Urbana-Champaign.

Simeon George, M.D., M.B.A.


Dr. George has served on Principia’s Board of Directors since 2011. Dr. George joined S.R. One in 2007 as an Associate, later became Partner and since February 2019, he has served as Chief Executive Officer. From 2006 to 2007, Dr. George was a consultant at Bain & Company, and in 2004, he was an investment banker at Goldman Sachs and Merrill Lynch.

Dr. George currently serves on the boards of Bird Rock Bio, CRISPR Therapeutics, eFFECTOR Therapeutics, Progyny, and Turning Point Therapeutics. Dr. George received a B.A. in neuroscience from Johns Hopkins University, where he graduated Phi Beta Kappa. He received a M.D. from the University of Pennsylvania School of Medicine and a M.B.A. (Mayer Scholar) from the Wharton School at the University of Pennsylvania.

Shao-Lee Lin, M.D., Ph.D.


Dr. Lin joined Principia’s Board of Directors in 2019. Dr. Lin is the former Executive Vice President, Head of Research and Development and Chief Scientific Officer of Horizon Pharma. Dr. Lin is an immunologist, a rheumatologist, and an allergist with more than 20 years of academic and clinical research experience. From 2015 to 2017, Dr. Lin was a corporate officer and Vice President, Therapeutic Areas, Development Excellence, and International Development at AbbVie where she led on-market and pipeline programs in immunology, virology, neuroscience, and general medicine, as well as international development across all therapeutic areas. From 2012 to 2015, Dr. Lin was Vice President, Inflammation and Respiratory Development at Gilead Sciences. She also held leadership positions in immunology and other therapeutic areas while at Amgen.

Dr. Lin received a M.D. and Ph.D. from Johns Hopkins University School of Medicine and completed fellowships and post-doctoral work in rheumatology, allergy, and immunology at the University of California, San Diego, and The Scripps Clinic and Research Institute. Dr. Lin received a B.S. in biochemistry and chemical engineering from Rice University. Dr. Lin has previously been on the faculty of Rockefeller University as a Clinical Scholar and also served as adjunct faculty at Cornell University, University of California, Los Angeles, Stanford, and Northwestern medical schools.

Patrick Machado


Mr. Machado joined Principia’s board in 2019. He co-founded Medivation in 2003 and served as its Chief Financial Officer from its inception until his retirement in 2014. From 2009, he also served as the company’s Chief Business Officer and, from 2014, as a member of the board of directors, until its acquisition by Pfizer in 2016. Prior to Medivation, his earlier experience included senior roles in finance, legal, and business development at ProDuct Health and Chiron. Earlier in his career, Mr. Machado worked for Morrison & Foerster LLP, an international law firm and for the Massachusetts Supreme Judicial Court.

Mr. Machado currently serves on the boards of Adverum Biotechnologies, Chimerix, and Turning Point Therapeutics. Mr. Machado received a J.D. from Harvard Law School and a B.A. in German and B.S. in Economics from Santa Clara University.

Shawn Tomasello

Former Chief Commercial Officer of Kite Pharma

Ms. Tomasello joined Principia’s Board of Directors in 2019. She brings more than 30 years of commercial and strategic experience in the pharmaceutical and biotech industries. From 2015 to 2018, Ms. Tomasello was Chief Commercial Officer at leading immuno-oncology cell therapy company Kite Pharma, which was acquired by Gilead Sciences. Prior to this, she served as Chief Commercial Officer and oversaw the launch of Imbruvica at Pharmacyclics, Inc., which was subsequently acquired by AbbVie, Inc. Ms. Tomasello previously was President of the Americas, Hematology and Oncology at Celgene Corporation where she managed over $4 billion in product revenues and was instrumental in various global expansion and acquisition strategies. She has also held senior positions at Genentech, Pfizer Laboratories, Miles Pharmaceuticals and Procter & Gamble.

Ms. Tomasello received an MBA from Murray State University and a B.S. in Marketing from the University of Cincinnati. She currently serves on the boards of Mesoblast Ltd, UroGen Pharma, Centrixion Therapeutics, Diplomat Rx and Oxford BioTherapeutics.

Partnering to Make a Difference